Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach

• Published in: Journal of ethnopharmacology Vol. 245; p. 112174
• Main Authors: Cusinato, Diego A.C., Martinez, Edson Z., Cintra, Mônica T.C., Filgueira, Gabriela C.O., Berretta, Andresa A., Lanchote, Vera L., Coelho, Eduardo B.
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 05.12.2019
• Subjects: Adult; ATP Binding Cassette Transporter, Subfamily B - metabolism; Caffeine - blood; Caffeine - pharmacokinetics; Clinical trials; Cross-Over Studies; Cytochrome P-450 Enzyme System - genetics; Cytochrome P-450 Enzyme System - metabolism; Drug Interactions; Drug metabolism; Drug transport; Female; Humans; Losartan - blood; Losartan - pharmacokinetics; Male; Metoprolol - blood; Metoprolol - pharmacokinetics; Midazolam - blood; Midazolam - pharmacokinetics; Omeprazole - blood; Omeprazole - pharmacokinetics; Pharmacokinetics; Propolis; Terfenadine - analogs & derivatives; Terfenadine - blood; Terfenadine - pharmacokinetics; Clinical trials; Drug metabolism; Drug transport; Pharmacokinetics; Propolis
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2019.112174

Propolis has been employed extensively in many cultures since ancient times as antiseptic, wound healing, anti-pyretic and others due to its biological and pharmacological properties, such as immunomodulatory, antitumor, anti-inflammatory, antioxidant, antibacterial, antiviral, antifungal, antiparasite activities. But despite its broad and traditional use, there is little knowledge about its potential interaction with prescription drugs. The main objective of this work was to study the potential herbal-drug interactions (HDIs) of EPP-AF® using an in vivo assay with a cocktail approach. Subtherapeutic doses of caffeine, losartan, omeprazole, metoprolol, midazolam and fexofenadine were used. Sixteen healthy adult volunteers were investigated before and after exposure to orally administered 125 mg/8 h (375 mg/day) EPP-AF® for 15 days. Pharmacokinetic parameters were calculated based on plasma concentration versus time (AUC) curves. After exposure to EPP-AF®, it was observed decrease in the AUC0−∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20 × 51.00 h.ng/mL), 8% (1085 × 999 h.ng/mL) and 13% (9.01 × 7.86 h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80–1.25. On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25. Changes in pharmacokinetics of metoprolol or its metabolite α-hydroxymetoprolol were not statistically significant and their 90% CIs were within the equivalence range of 0.80–1.25. In conclusion, our study shows that EPP-AF® does not clinically change CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A activities, once, despite statistical significant, the magnitude of the changes in AUC values after EPP-AF® were all below 20% and therefore may be considered safe regarding potential interactions involving these enzymes. Besides, to the best of our knowledge this is the first study to assess potential HDIs with propolis. [Display omitted]